These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 26722067

  • 1. ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography for Evaluating the Response to Neoadjuvant Chemotherapy in Advanced Esophageal Cancer.
    Tani Y, Nakajima M, Kikuchi M, Ihara K, Muroi H, Takahashi M, Domeki Y, Okamoto K, Yamaguchi S, Sasaki K, Tsuchioka T, Sakamoto S, Kato H.
    Anticancer Res; 2016 Jan; 36(1):367-73. PubMed ID: 26722067
    [Abstract] [Full Text] [Related]

  • 2. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
    Miyata H, Yamasaki M, Takahashi T, Murakami K, Tanaka K, Yukinori K, Nakajima K, Takiguchi S, Morii E, Hatazawa J, Mori M, Doki Y.
    Ann Surg Oncol; 2014 Feb; 21(2):575-82. PubMed ID: 24201746
    [Abstract] [Full Text] [Related]

  • 3. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
    Odawara S, Kitajima K, Katsuura T, Kurahashi Y, Shinohara H, Yamakado K.
    Eur J Radiol; 2018 Apr; 101():65-71. PubMed ID: 29571803
    [Abstract] [Full Text] [Related]

  • 4. Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Izumi D, Yoshida N, Watanabe M, Shiraishi S, Ishimoto T, Kosumi K, Tokunaga R, Taki K, Higashi T, Harada K, Miyata T, Ida S, Imamura Y, Iwagami S, Baba Y, Sakamoto Y, Miyamoto Y, Yamashita Y, Baba H.
    J Gastroenterol; 2016 Aug; 51(8):788-95. PubMed ID: 26671045
    [Abstract] [Full Text] [Related]

  • 5. Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
    Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC.
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [Abstract] [Full Text] [Related]

  • 6. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G, Petyt G, Duhamel A, Mirabel X, Huglo D, Mariette C.
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [Abstract] [Full Text] [Related]

  • 7. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D, Hölscher AH, Dietlein M, Bollschweiler E, Baldus SE, Mönig SP, Metzger R, Schicha H, Schmidt M.
    Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
    [Abstract] [Full Text] [Related]

  • 8. The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.
    Choi EK, Yoo IR, Kim SH, Park SY, O JH, Kang BJ.
    Acta Radiol; 2018 Jan; 59(1):41-49. PubMed ID: 28427271
    [Abstract] [Full Text] [Related]

  • 9. 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer.
    Champion L, Lerebours F, Alberini JL, Fourme E, Gontier E, Bertrand F, Wartski M.
    J Nucl Med; 2015 Sep; 56(9):1315-21. PubMed ID: 26159587
    [Abstract] [Full Text] [Related]

  • 10. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
    Groheux D, Hindié E, Giacchetti S, Hamy AS, Berger F, Merlet P, de Roquancourt A, de Cremoux P, Marty M, Hatt M, Espié M.
    Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
    [Abstract] [Full Text] [Related]

  • 11. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT, Oksala N, Salo JA, Helin H, Karhumäki L, Kemppainen J, Sihvo EI, Räsänen JV.
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [Abstract] [Full Text] [Related]

  • 12. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
    Lee HY, Lee HJ, Kim YT, Kang CH, Jang BG, Chung DH, Goo JM, Park CM, Lee CH, Kang KW.
    J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
    [Abstract] [Full Text] [Related]

  • 13. Volume-based metabolic tumor response to neoadjuvant chemotherapy is associated with an increased risk of recurrence in breast cancer.
    Hyun SH, Ahn HK, Park YH, Im YH, Kil WH, Lee JE, Nam SJ, Cho EY, Choi JY.
    Radiology; 2015 Apr; 275(1):235-44. PubMed ID: 25496075
    [Abstract] [Full Text] [Related]

  • 14. PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer.
    Duch J, Fuster D, Muñoz M, Fernández PL, Paredes P, Fontanillas M, Skaltsa K, Domènech B, Lomeña F, Pons F.
    Q J Nucl Med Mol Imaging; 2012 Jun; 56(3):291-8. PubMed ID: 22695339
    [Abstract] [Full Text] [Related]

  • 15. Accuracy and reproducibility of 3D-CT measurements for early response assessment of chemoradiotherapy in patients with oesophageal cancer.
    van Heijl M, Phoa SS, van Berge Henegouwen MI, Omloo JM, Mearadji BM, Sloof GW, Bossuyt PM, Hulshof MC, Richel DJ, Bergman JJ, Ten Kate FJ, Stoker J, van Lanschot JJ.
    Eur J Surg Oncol; 2011 Dec; 37(12):1064-71. PubMed ID: 21944048
    [Abstract] [Full Text] [Related]

  • 16. MRI and FDG-PET for assessment of response to neoadjuvant chemotherapy in locally advanced rectal cancer.
    Aiba T, Uehara K, Nihashi T, Tsuzuki T, Yatsuya H, Yoshioka Y, Kato K, Nagino M.
    Ann Surg Oncol; 2014 Jun; 21(6):1801-8. PubMed ID: 24531702
    [Abstract] [Full Text] [Related]

  • 17. Different 18 F-FDG PET parameters for the prediction of histological response to neoadjuvant chemotherapy in pediatric Ewing sarcoma family of tumors.
    El-Hennawy G, Moustafa H, Omar W, Elkinaai N, Kamel A, Zaki I, Farid N, El-Kholy E.
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28605. PubMed ID: 32706520
    [Abstract] [Full Text] [Related]

  • 18. Comparison of (18)F-FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal cancer.
    Altini C, Niccoli Asabella A, De Luca R, Fanelli M, Caliandro C, Quartuccio N, Rubini D, Cistaro A, Montemurro S, Rubini G.
    Abdom Imaging; 2015 Jun; 40(5):1190-202. PubMed ID: 25348731
    [Abstract] [Full Text] [Related]

  • 19. Metabolic Tumor Volume Change Predicts Long-term Survival and Histological Response to Preoperative Chemotherapy in Locally Advanced Esophageal Cancer.
    Makino T, Yamasaki M, Tanaka K, Masuike Y, Tatsumi M, Motoori M, Kimura Y, Hatazawa J, Mori M, Doki Y.
    Ann Surg; 2019 Dec; 270(6):1090-1095. PubMed ID: 29727327
    [Abstract] [Full Text] [Related]

  • 20. Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer.
    Chung YS, Kim HS, Lee JY, Kang WJ, Nam EJ, Kim S, Kim SW, Kim YT.
    Cancer Res Treat; 2020 Oct; 52(4):1211-1218. PubMed ID: 32599990
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.